Aktuelle Ernährungsmedizin 2017; 42(03): 241-272
DOI: 10.1055/s-0037-1603284
Poster
Georg Thieme Verlag KG Stuttgart · New York

EFFECT OF AN ORAL GLUCOSE CHALLENGE ON GLP-1 SECRETION IN OBESE AND NORMAL WEIGHT ADOLESCENTS

Authors

  • V Heu

    1   Universitätsklinik für KInder- und Jugendheilkunde, PMU, Salzburg, Austria

  • P Bergsten

    2   Department of Medical Cell Biology

  • M Dahlbom

    3   Department of Women's and Children's Health, Uppsala University

  • A Forslund

    3   Department of Women's and Children's Health, Uppsala University
    4   Uppsala University Children's Hospital, Uppsala, Finland

  • L Kedenko

    5   Paracelsus Medizinische Privatuniversität, Universitätsklinik für Innere Medizin I

  • H Manell

    2   Department of Medical Cell Biology

  • K Paulmichl

    6   Paracelsus Medizinische Privatuniversität, Universitätsklinik für KInder- und Jugendheilkunde, Salzburg, Austria

  • K Widhalm

    6   Paracelsus Medizinische Privatuniversität, Universitätsklinik für KInder- und Jugendheilkunde, Salzburg, Austria

  • F Zsoldos

    6   Paracelsus Medizinische Privatuniversität, Universitätsklinik für KInder- und Jugendheilkunde, Salzburg, Austria
    7   Obesity Research Unit, Uppsala University, Uppsala, Finland

  • D Weghuber

    1   Universitätsklinik für KInder- und Jugendheilkunde, PMU, Salzburg, Austria
    7   Obesity Research Unit, Uppsala University, Uppsala, Finland
Further Information

Publication History

Publication Date:
20 June 2017 (online)

Also available at
 

Introduction:

Prevalence of obesity in childhood and adolescence is increasing (1), overweight or obese children are at high risk for metabolic comorbidities like impaired glucose tolerance (IGT), dyslipidemia, hypertension, premature arteriosclerosis and non alcoholic fatty liver disease (NAFLD) (2). The role of GLP-1 in juvenile obesity and associated metabolic comorbidities remains to be elucidated.

Objectives:

The aim of the pilot study was to examine potential differences between nomal weight and obese adolescents (with or without IGT/NAFLD) regarding their GLP-1 response to orally administered glucose.

Methods:

29 adolescents with normal body weight (15 ± 1.7 years, 166.5 ± 10.7 cm, 58.6 ± 10.8 kg, 0.3 ± 0.8 BMI-SDS) and 52 obese adolescents (13.5 ± 2.0 years, 162.9 ± 11.5 cm, 84.4 ± 20.4 kg, 2.8 ± 0.6 BMI-SDS) were included. Oral glucose challenge was performed (1.75 g glucose/kg bodyweight, max. 75 g), blood samples were collected at -5 min/5 min/10 min/15 min/30 min/60 min/90 min/120 min/180 min, total GLP-1 and active GLP-1 were analysed by ELISA. IGT was defined as blood glucose > 140 – 199 mg/dl (oGTT 120 minutes), NAFLD as alaninaminotransferase (ALT) (baseline) > 24 mg/dl. Statistical analysis was carried out with Mann Whitney Test, Microsoft Excel 2010, Prism Graphpad 5.04.

Results:

There is no difference between the groups regarding total GLP-1. Obese adolescents show significantly lower active GLP-1 levels compared to normal weight adolescents [normal weight (n = 29) vs. obese (n = 51, p = 0.027)/obese with IGT (n = 9, p = 0.013)/NAFLD (n = 28, p = 0.002)], obese adolescents divided in ALT-quartiles show significant differences (highest vs. lowest quartile, p = 0.009).

Conclusion:

Obese adolescents (with IGT or NAFLD) show significantly lower active GLP-1 response compared to normal weight adolescents after an oral glucose challenge, there are no differences regarding total GLP-1. This is relevant due to the option for GLP-1 receptoragonists as treatment for obese adolescents (and associated comorbidities). Further research is needed.

References:

[1] Group WHOMGRS. WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr Suppl. 2006;450:76 – 85.

[2] Litwin SE. Childhood obesity and adulthood cardiovascular disease: quantifying the lifetime cumulative burden of cardiovascular risk factors. J Am Coll Cardiol. 2014;64(15):1588 – 90.

Disclosure of Interest:

None declared.